Clinical Trial Update: A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of JAB-21822 in advanced or metastatic non-small cell lung cancer with KRAS p.G12C and STK11 co-mutation and KEAP1 wild-type; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JAB-21822

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING